Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia

Novel therapies are needed to overcome chemotherapy resistance for children with relapsed/refractory acute lymphoblastic leukemia (ALL). Moxetumomab pasudotox is a recombinant anti-CD22 immunotoxin. A multicenter phase 1 study was conducted to determine the maximum-tolerated cumulative dose (MTCD) a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Wayne, Alan S., Shah, Nirali N., Bhojwani, Deepa, Silverman, Lewis B., Whitlock, James A., Stetler-Stevenson, Maryalice, Sun, Weili, Liang, Meina, Yang, Jie, Kreitman, Robert J., Lanasa, Mark C., Pastan, Ira
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2017
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5630009/
https://ncbi.nlm.nih.gov/pubmed/28983018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-02-749101
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars